Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd lowered its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 31.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,958 shares of the company’s stock after selling 3,617 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Axsome Therapeutics were worth $715,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in AXSM. Arizona State Retirement System increased its position in Axsome Therapeutics by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 8,630 shares of the company’s stock valued at $695,000 after acquiring an additional 177 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Axsome Therapeutics by 22.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock worth $156,000 after purchasing an additional 318 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new stake in Axsome Therapeutics in the second quarter worth approximately $27,000. WCM Investment Management LLC boosted its stake in Axsome Therapeutics by 0.3% during the 3rd quarter. WCM Investment Management LLC now owns 113,692 shares of the company’s stock valued at $10,191,000 after purchasing an additional 347 shares in the last quarter. Finally, US Bancorp DE increased its position in shares of Axsome Therapeutics by 0.3% during the 3rd quarter. US Bancorp DE now owns 133,126 shares of the company’s stock valued at $11,964,000 after purchasing an additional 421 shares during the period. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Stock Performance

AXSM stock opened at $90.10 on Friday. The stock has a market cap of $4.37 billion, a P/E ratio of -13.80 and a beta of 1.18. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 and a current ratio of 2.44. The firm has a 50 day simple moving average of $93.02 and a 200 day simple moving average of $87.31. Axsome Therapeutics, Inc. has a 52 week low of $64.11 and a 52 week high of $105.00.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The business had revenue of $104.76 million for the quarter, compared to analysts’ expectations of $98.71 million. During the same period in the previous year, the company posted ($1.32) EPS. Research analysts anticipate that Axsome Therapeutics, Inc. will post -4.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on AXSM shares. HC Wainwright reaffirmed a “buy” rating and set a $180.00 target price on shares of Axsome Therapeutics in a research note on Monday, November 25th. StockNews.com raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Wells Fargo & Company began coverage on shares of Axsome Therapeutics in a research note on Tuesday, September 3rd. They set an “overweight” rating and a $140.00 target price for the company. Robert W. Baird lifted their price target on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Finally, Royal Bank of Canada increased their price objective on Axsome Therapeutics from $130.00 to $131.00 and gave the company an “outperform” rating in a research report on Friday, October 4th. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Axsome Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $125.93.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.